ALGS Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Aligos Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.53 |
52 Week High | US$1.20 |
52 Week Low | US$0.35 |
Beta | 2.19 |
11 Month Change | 5.16% |
3 Month Change | -33.19% |
1 Year Change | -49.44% |
33 Year Change | -96.49% |
5 Year Change | n/a |
Change since IPO | -96.46% |
Recent News & Updates
Aligos Therapeutics (NASDAQ:ALGS) Will Have To Spend Its Cash Wisely
Jul 16Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 27% Dip In Price Shows Sentiment Is Matching Revenues
May 24Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Apr 09Recent updates
Aligos Therapeutics (NASDAQ:ALGS) Will Have To Spend Its Cash Wisely
Jul 16Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 27% Dip In Price Shows Sentiment Is Matching Revenues
May 24Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Apr 09Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues
Feb 23Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation
Oct 24We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully
Jul 17We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully
Mar 11Aligos Therapeutics begins 12-week dosing in phase 1b study to treat hepatitis B
Jul 25We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate
Jul 11We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate
Feb 02Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation
Oct 19Aligos Therapeutics EPS beats by $0.16
May 10We're Hopeful That Aligos Therapeutics (NASDAQ:ALGS) Will Use Its Cash Wisely
May 01What Is The Ownership Structure Like For Aligos Therapeutics, Inc. (NASDAQ:ALGS)?
Jan 16Dosing underway for Aligos Therapeutics' hepatitis B candidate in early-stage study
Oct 30Shareholder Returns
ALGS | US Biotechs | US Market | |
---|---|---|---|
7D | 11.3% | 4.5% | 1.3% |
1Y | -49.4% | 13.6% | 22.0% |
Return vs Industry: ALGS underperformed the US Biotechs industry which returned 13.6% over the past year.
Return vs Market: ALGS underperformed the US Market which returned 22% over the past year.
Price Volatility
ALGS volatility | |
---|---|
ALGS Average Weekly Movement | 11.1% |
Biotechs Industry Average Movement | 10.5% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 14.8% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ALGS's share price has been volatile over the past 3 months.
Volatility Over Time: ALGS's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2018 | 67 | Larry Blatt | www.aligos.com |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB.
Aligos Therapeutics, Inc. Fundamentals Summary
ALGS fundamental statistics | |
---|---|
Market cap | US$39.83m |
Earnings (TTM) | -US$99.59m |
Revenue (TTM) | US$13.79m |
3.0x
P/S Ratio-0.4x
P/E RatioIs ALGS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ALGS income statement (TTM) | |
---|---|
Revenue | US$13.79m |
Cost of Revenue | US$71.27m |
Gross Profit | -US$57.48m |
Other Expenses | US$42.11m |
Earnings | -US$99.59m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.27 |
Gross Margin | -416.76% |
Net Profit Margin | -722.06% |
Debt/Equity Ratio | 0% |
How did ALGS perform over the long term?
See historical performance and comparison